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The development of novel efficient substances for anticancer chemotherapy is an important 
problem of medicinal chemistry. Aim. To evaluate the level of cytotoxic action of novel thia-
zole derivatives towards tumor cell lines of different origin. Methods. Four N acylated 
2-amino-5-benzyl-1,3-thiazoles (5a–d) were synthesized by reaction of 2-amino-5-R-ben-
zyl-1,3-thiazoles with acid chlorides in the presence of triethylamine in the dioxane medium. 
Anticancer screening of the synthesized thiazoles was performed by the MTT assay. Results. 
Thiazole derivatives were shown to exert antineoplastic activity towards different types of 
tumor cells. The anti-glioma and anti-melanoma selectivity of these derivatives action was 
demonstrated. The compound 5a was found to be the most toxic for human glioblastoma U251 
cells and human melanoma WM793 cells. At the same time, the created compounds possessed 
low toxicity towards pseudo-normal cells. Conclusion. The novel thiazole derivative 5a was 
the most toxic against human glioblastoma and melanoma cells.
K e y w o r d s: thiazole derivatives, 2-amino-5-benzyl-1,3-thiazoles, anticancer activity, leu-
kemia, glioblastoma, melanoma.
Introduction 
The discovery and development of the con-
ventional anticancer drugs have been mainly 
focused on the cytotoxic agents [1]. The per-
spective antineoplastic agents are expected to 
inhibit, delay or reverse the progression of 
cancer development through their cytotoxicity 
or apoptosis-inducing properties [2]. Cytotoxic 
drugs prevent the rapid growth and division 
(mitosis) of tumor cells [1]. However, many 
anticancer drugs do not possess enough selec-
tivity towards their targets. Thus, their applica-
tion for cancer treatment is associated with 
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numerous negative side effects in the orga-
nism [3, 4]. Drugs demonstrate cytotoxicity 
toward different normal cells and organs, in-
cluding bone marrow cells, reproductive 
glands, mucous layer of the intestine and hair 
follicles. These effects limit significantly ap-
plication of some drugs and lead to the devel-
opment of novel drugs.
Thiazole derivatives have attracted the in-
terest of medicinal chemists due to a variety 
of their biological activities including anti-
bacterial, anti-fungal, anti-HIV, anti-hyperten-
sion, anti-inflammatory, anti-cancer, anti-con-
vulsive and anti-depressant [5–10]. The mech-
anisms of 1,3-thiazole derivatives antitumor 
activity may be associated with DNA interca-
lation [11, 12], PRL-3, SHP-2 and JSP-1 inhi-
bition [13–16], tumor necrosis factor 
(TNFα) [17], anti-apoptotic bio-complex Bcl-
XL-BH3 [18], integrin avb3 [19], others. 
Thiazole ring belongs to the privileged scaf-
folds in modern medicinal chemistry [11, 20, 
21], particularly at discovering new anticancer 
agents. 
Herein, we described novel N-acylated 
2-amino-5-benzyl-1,3-thiazoles and discovered 
N2
+ -
O
CuCl2 Cl
Cl
O NH2 NH2
S
S
N
NH2
R R
R
EtOH, t
NEt3, dioxane
R1 Cl
O
S
N
N
H
R1
OR
acetone/H2O
1a-d
1, 2, 3:  R = H (a), 4-Et (b), 4-Br (c), 3,4-Cl2 (d)
3a-d2a-d
5a-d
4a-d
Entry Compounds Entry Compounds
5a
S
N
N
H
O O
S
N
N
H
Et
O
S
O
S
N
N
HBr
O O
S
N
N
HCl
OCl
O
5c
S
N
N
H
O O
S
N
N
H
Et
O
S
O
S
N
N
HBr
O O
S
N
N
HCl
OCl
O
5b
S
N
N
H
O O
S
N
N
H
Et
O
S
O
S
N
N
HBr
O O
S
N
N
HCl
OCl
O
5d
S
N
N
H
O O
S
N
N
H
Et
O
S
O
S
N
N
HBr
O O
S
N
N
HCl
OCl
O
Fig. 1. General scheme of synthesis of thiazole derivatives 
137
Antineoplastic activity of novel thiazole derivatives
anticancer activity of the obtained amides. The 
synthesis of the target acylated 5-R-benzyl-
1,3-thiazol-2-amines 5 is presented in Fig. 1. 
At the first step, the acrolein reacts with arene-
diazonium salts (1a–d) in the presence of 
copper(II) chloride under the Meerwein aryla-
tion conditions. 3-Aryl-2-chloropropanals 
(2a–d) react with the thiourea in ethanol at 
refluxing and form 2-amino-5-R-benzyl-1,3-
thiazoles (3a–d) with good yield [22, 23]. 
Previously, we have discussed the synthetic 
possibilities of 5-benzyl-2-aminothiazoles du-
ring the synthesis of 2-[(5-benzyl-1,3-thiazol-
2-yl)imino]-1,3-thiazolidin-4-ones as potential 
biologically active compounds [24, 25]. In this 
paper, we described N-acylated 2-amino-
5-benzyl-1,3-thiazoles (5a–d) obtained by the 
reaction of 2-amino-5-R-benzyl-1,3-thiazoles 
3a–d with acid chlorides 4a–d in the presence 
of trietylamine in the dioxane medium. 
The present study was addressed on the 
synthesis of thiazole derivatives containing 
some heterocyclic cores and the evaluation of 
their anticancer activity towards tumor cell 
lines of different tissue origin.
Materials and Methods
Thiazole derivatives
A 10 mM stock solution of thiazole derivatives 
was prepared in the dimethyl sulfoxide 
(DMSO, Sigma-Aldrich, USA), and addition-
ally dissolved in a culture medium prior to 
addition to the cell culture.
General Procedure for the Synthesis 
of 3-aryl-2-chloropropanales 2a–d [23]
A three-necked flask equipped with a dropping 
funnel, a stirrer, and a gas-outlet tube attached 
to a bubble counter was charged with acrolein 
(0.2 mol or 13.5 cm3), CuCl2·2H2O (10 g), and 
acetone (50 cm3). Then, cold aqueous solution 
of arenediazonium chloride 1a–d prepared by 
diazotization of aniline (0.2 mol) was added 
drop-wise to the flask under vigorous stirring. 
The temperature of the mixture was kept with-
in 10–30 °C. The organic phase was separated 
when the reaction was completed, and the 
aqueous phase was extracted with chloroform. 
The extract was combined with the previous 
organic phase, dried over magnesium sulfate, 
evaporated, and the residue was distilled under 
reduced pressure.
General Procedure for the Synthesis 
of 2-amino-5-arylmethylthiazoles 3a–d
A mixture of 8 g of thiourea and 0.1 mol of 
3-aryl-2-chloropropanal 2a–d in 50 cm3 of 
ethanol was heated for 2 h under reflux. Then, 
it was cooled, diluted with 300 cm3 of water, 
and alkaline pH (~ 9) was achieved by adding 
aqueous ammonia. The precipitate was filtered 
off and recrystallized from carbon tetrachlo-
ride. 5-Benzyl-1,3-thiazol-2-amine 3a has been 
described earlier [22, 23].
5-(4-Ethylbenzyl)-1,3-thiazol-2-amine 
3b.Yield 86 %. M.p. 105–106 °C. 1H NMR 
(400 MHz, DMSO-d6), δ: 7.11 (d, J = 7.8 Hz, 
2H), 7.08 (d, J = 7.8 Hz, 2H), 6.64 (s, 1Н), 
6.60 (s, 2Н), 3.81 (s, 2H), 2.58 (q, J = 7.7 Hz, 
2H), 1.19 (t, J = 7.6 Hz, 3H). Calculated, %: 
C 66.02, Н 6.46, N 12.83. C12H14N2S. Found: 
C 65.85, Н 6.33, N 12.58.
5-(4-Bromobenzyl)-1,3-thiazol-2-amine 3c. 
Yield 84 %. M.p. 123–125 °C. 1H NMR 
(400 MHz, DMSO-d6), δ: 7.42 (d, 2Н, J = 
8.1 Hz), 7.15 (d, 2Н, J= 8.1 Hz), 6.61 (s, 2Н), 
6.64 (s, 1Н), 3.86 (s, 2Н). Calculated, %: 
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44.62, Н 3.37, N 10.41.  C10H9BrN2S. Found: 
C 44.34, Н 3.32, N 10.25.
5-(3,4-Dichlorobenzyl)-1,3-thiazol-2-amine 
3d. Yield 83%. M.p. 92–94°C. 1H NMR 
(400 MHz, DMSO-d6), δ: 7.47 (d, 1Н, 
J=8.4 Hz), 7.40 (d, 1Н, J=1.8 Hz), 7.17 (dd, 
1Н, 4J=1.8 Hz, 3J=8.4 Hz), 6.67 (br. s, 3Н), 
3.90 (s, 2Н). Calculated, %: C 46.35, Н 3.11, 
N 10.81. C10H8Cl2N2S. Found: C 46.22, 
Н 3.08, N 10.69.
General Procedure for the Synthesis 
of compounds 5a–d
5 mmol of 2-amino-5-arylmethylthiazole 3a–d 
was dissolved in the mixture of 5 ml dioxane 
and 5 mmol triethylamine. Solution of 5 mmol 
acid chloride 4a–d in 3 ml dioxane was added 
drop-wise to the reaction mixture under vigor-
ous stirring. Mixture was stirred for 2 h, and 
diluted with 50 cm3 of water. The precipitate 
was filtered off and recrystallized from mixture 
EtOH/DMF. 
N-(5-Benzyl-1,3-thiazol-2-yl)-3,5-dimethyl-
1-benzofuran-2-carboxamide 5a. Yield 75 %. 
M.p. 198 °C. 1H NMR (400 MHz, DMSO-d6), 
δ: 12.42 (s, 1H), 7.54 (s, 1H), 7.49 (d, 1H, J = 
8.5 Hz,), 7.35–7.26 (m, 6H), 7.25–7.21 (m, 
1H), 4.10 (s, 2H), 2.54 (s, 3H), 2.42 (s, 3H). 
13C NMR (100 MHz, DMSO-d6), δ: 152.10, 
142.44, 140.64, 133.87, 133.04, 131.92, 
131.80, 129.66, 129.55, 129.07, 129.01, 
128.89, 126.98, 124.10, 121.23, 111.93, 32.54, 
21.36, 9.39. Calculated, %: C, 69.59; H, 5.01; 
N, 7.73. C21H18N2O2S. Found: C, 69.29; H, 
4.94; N, 7.63.
N-[5-(4-Ethylbenzyl)-1,3-thiazol-2-yl]-1-
oxo-1H-isothiochromene-3-carboxamide 5b. 
Yield 83 %. M.p. 190 °C. 1H NMR (400 MHz, 
DMSO-d6), δ: 13.09 (s, 1H), 8.36 (s, 1H), 8.18 
(d, 1H, J = 7.9 Hz), 7.99–7.88 (m, 2H), 7.77 
(t, 1H, J = 7.1 Hz), 7.33 (s, 1H), 7.19 (d, 2H, 
J = 7.7 Hz), 7.16 (d, 2H, J = 8.1 Hz), 4.02 (s, 
2H), 2.56 (q, 2H J = 7.7 Hz), 1.15 (t, 3H, J = 
7.5 Hz). 13C NMR (101 MHz, DMSO-d6),δ: = 
187.30, 156.46, 155.32, 146.97, 142.55, 
137.57, 136.91, 135.26, 132.92, 131.54, 
129.01, 128.86, 128.77, 128.55, 128.48, 
128.46, 125.67, 32.43, 28.26, 16.11. Calculated, 
%: C, 65.00; H, 4.46; N, 6.89. C22H18N2O2S2. 
Found: C, 64.57; H, 4.39; N, 6.75.
N-[5-(4-Bromobenzyl)-1,3-thiazol-2-yl]-2-
(2,4-dimethylphenoxy)acetamide 5c. Yield 
80 %. M.p. 150°C. 1H NMR (400 MHz, 
DMSO-d6), δ: 12.15 (s, 1H), 7.49 (d, 2H,J = 
8.2 Hz), 7.26 (s, 1H), 7.21 (d, 2H, J = 8.2 Hz), 
6.95 (s, 1H), 6.89 (d, 1H, J = 8.2 Hz), 6.66 (d, 
1H, J = 8.2 Hz), 4.77 (s, 2H), 4.06 (s, 2H), 
2.17 (s, 3H), 2.16 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6), δ:162.19, 162.12, 154.31, 140.20, 
135.40, 131.90, 131.82, 131.47, 131.09, 
130.06, 127.46, 126.33, 120.03, 111.72, 66.91, 
31.65, 20.52, 16.48. Calculated, %: C, 55.69; 
H, 4.44; N, 6.49. C20H19BrN2O2S. Found: C, 
55.32; H, 4.39; N, 6.33.
N-[5-(3,4-Dichlorobenzyl)-1,3-thiazol-2-
yl]-2H-chromene-2-carboxamide 5d. Yield 
85%. M.p. 216°C. 1H NMR (400 MHz, 
DMSO-d6), δ: 12.32 (s, 1H), 7.69 (s, 1H), 7.57 
(d, 2H, J = 8.3 Hz), 7.33 (s, 1H), 7.31–7.22 
(m, 3H), 6.99–6.95 (m, 1H), 6.86 (d, 1H, J = 
8.0 Hz), 4.98 (s, 2H), 4.12 (s, 2H). 13C NMR 
(101 MHz, DMSO-d6), δ: = 154.88, 142.01, 
132.33, 132.22, 131.50, 131.47, 131.19, 
131.14, 130.84, 130.76, 129.58, 129.50, 
129.46, 129.33, 129.27, 122.44, 121.38, 
116.28, 64.44, 31.21. Calculated, %: C, 57.56; 
H, 3.38; N, 6.71. C20H14Cl2N2O2S. Found: C, 
57.30; H, 3.31; N, 6.62.
139
Antineoplastic activity of novel thiazole derivatives
Cell culture
Human breast adenocarcinoma cells of MCF-
7 line, lung adenocarcinoma cells of A549 line, 
glioblastoma cells of U251 line, myeloid 
leukemia cells of K562 line, acute T-cell leuke-
mia cells of Jurkat line, and embryonic kidney 
cells of HEK293 line were obtained from Cell 
Collection of R.E. Kavetsky Institute of 
Experimental Pathology, Oncology and 
Radiology (Kyiv, Ukraine). Human melanoma 
cells of WM793 line were provided by Dr. O. 
Stasyk (Institute of Cell Biology, National 
Academy of Sciences of Ukraine, Lviv, 
Ukraine). Cells were grown in the RPMI (APP, 
Austria) or DMEM (Sigma-Aldrich, USA) 
culture medium supplemented with 10 % fetal 
bovine serum (FBS, APP, Austria). Cells were 
cultivated in the CO2-thermostate at 37oC in 
atmosphere of 95 % air and 5 % CO2.
Cell proliferation assay
Antineoplastic activity of the synthesized 
compounds towards cancer cell lines was mea-
sured by the MTT (3-(4,5-Dimethylthiazole-
2-yl)-2,5-diphenyl-tetrazolium bromide) test 
(Sigma-Aldrich, USA) [26]. The antitumor 
drug doxorubicin (Pharmachemie B.V., the 
Netherlands) was used as a reference drug 
control. Tumor cells were seeded for 24 h in 
96-well plates in 100 μl at the concentration 
of 5,000 cells/well (substrate-dependent cells) 
or 10,000 cells/well (suspension cells). After 
that, cells were incubated for next 72 h with 
various additions of the synthesized com-
pounds or doxorubicin (0–100 μM). MTT was 
added to the cells according to the manufac-
turer’s protocol (Sigma-Aldrich, USA). The 
results of the reaction were determined by an 
Absorbance Reader BioTek ELx800 (BioTek 
Instruments, Inc., USA). The IC50 of tested 
compounds was calculated as a lethal concen-
tration of drug killing 50 % of the cells in 
comparison with an untreated culture.
Statistical analysis
All data are presented as the mean ± standard 
deviation. The results were analyzed and il-
lustrated with GraphPad Prism (version 6; 
GraphPad Software, USA). Statistical analysis 
was performed using two-way ANOVA tests. 
P-value of <0.05 was considered as statisti-
cally significant.
Results
The synthesis of different derivatives of 
2-amino-5-arylmethylthiazoles is described 
in the Materials and Methods section. The 
compounds under study were added to the 
cultured human tumor and pseudo-normal 
cells in different final concentrations (0; 1; 
10; 50 μM) for 72 h. Doxorubicin was used 
as a reference positive control. The obtained 
results were expressed as IC50 and presented 
in Figures 2–4. The synthesized thiazoles 
were shown to possess diverse anti-prolifer-
ative action towards tumor cells of different 
tissue origin.
In the first set of experiments, the antican-
cer effect of compounds was studied towards 
adenocarcinoma cells, namely human breast 
adenocarcinoma cells of MCF-7 line and hu-
man lung adenocarcinoma cells of A549 line. 
Doxorubicin demonstrated a much stronger 
cytotoxicity for MCF-7 cells comparing to 
the A549 cells (Fig. 2). However, both cell 
lines were relatively not sensitive to the ac-
tion of studied thiazoles used in doses up to 
50 μM. 
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The antineoplastic effect of the thiazole 
derivatives was also studied using human glio-
blastoma cells of U251 line and human mela-
noma cells of WM793 line. The concentration-
dependent cytotoxicity effect of the thiazoles 
was found when the glioblastoma cells were 
treated. The synthesized 5c, 5d and 5b dis-
played a weak activity towards glioblastoma 
U251 cells (IC50 for 5c was 40.0±2.46 μM; 
IC50 for 5d was 36.5±1.96 μM and IC50 for 5b 
was 40.0±2.82 μM), and demonstrated cyto-
toxicity only when used in high dose (50 μM). 
At the same time, the 5a compound was high-
ly toxic for the glioblastoma cells (IC50 = 
9.8±0.82 μM), and even more toxic than the 
doxorubicin (IC50 = 21.0±1.64 μМ) that is 
considered to be a “golden standard” in the 
anticancer chemotherapy (Fig. 3).
The general pattern of the cytotoxic activ-
ity of 5a–d thiazoles and doxorubicin towards 
human melanoma cells of WM793 line was 
similar to that described above for human 
glioblastoma U251 cells. IC50 for 5c was 
32.3±2.15 μM, IC50 for 5d was 34.6±2.24 μM, 
 
Fig. 2. Characteristics of cytotoxicity of thiazole derivatives (5a–d) and doxorubicin (Dox) towards human breast 
adenocarcinoma MCF-7 cells and human lung adenocarcinoma A549 cells. 
Fig. 3. Characteristics of cytotoxicity of thiazole derivatives (5a–d) and doxorubicin (Dox) towards human glioblas-
toma U251 cells and human melanoma WM793 cells. 
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and IC50 for 5b was 28.5±2.06 μM, whereas 
the 5a compound was highly toxic for the 
melanoma cells (IC50 = 7.2±0.48 μM), and the 
toxicity of doxorubicin was similar to such 
effect of the 5a compound (IC50 = 6.1±0.38 μM) 
(Fig. 3).
As four human tumor cell lines used above 
belong to the substrate-dependent type of cells, 
it was reasonable to study the effect of 5a–d 
thiazoles and doxorubicin on the inhibition of 
growth of the leukemia cells in suspension. 
Thus, human myeloid leukemia cells of K562 
line and human acute T-cell leukemia cells of 
Jurkat line were treated in vitro with the doxo-
rubicin and experimental anticancer agents. 
We have found that 5c and 5b compounds 
possessed a moderate toxicity for leukemia 
K-562 cells (IC50 for 5c was 40.0±2.65 μM 
and IC50 for 5b was 44.7±3.15μM). 5d and 5a 
compounds were relatively non-toxic for the 
leukemia K-562 cells in the concentration up 
to 50 μM (Fig. 4), whereas the toxicity of 
doxorubicin was much higher comparing to 
the effect of thiazoles and IC50 for doxorubicin 
was 15.2±1.14 μM.
It was found that 5c, 5a and 5b did not 
demonstrate significant toxicity for human 
acute T-cell leukemia cells of Jurkat line 
(IC50 for 5a was 27.0±2.13 μM, IC50 for 5c 
was 32.3±2.73 μM, and IC50 for 5b was 
33.0± 2.85 μM). The 5d was poorly active 
towards the Jurkat leukemia cells in dose to 
50 μM, whereas the doxorubicin was ex-
tremely to xic for these cells (IC50 = 
0.7±0.05 μM) (Fig. 4).
Fig. 4. Characteristics of cytotoxicity of thiazole derivatives (5a–d) and doxorubicin (Dox) towards human myeloid 
leukemia cells of K562 line and human acute T-cell leukemia cells of Jurkat line.
Fig. 5. Characteristics of cytotoxicity of thiazole deriva-
tives (5a–d) and doxorubicin (Dox) towards human em-
bryonic kidney cells of HEK 293 line. 
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Thus, the tested thiazole derivatives showed 
a broad spectrum of the growth inhibition 
activity against human tumor cells of different 
tissue origin and the melanoma and glioma 
cells appeared to be more sensitive to the ac-
tion of these derivatives comparing to human 
leukemia cells.
Finally, we have studied the cytotoxic effect 
of the novel thiazoles towards non-tumor pseu-
do-normal cells – human embryonic kidney 
cells of HEK293 line (Fig. 5). Notably, these 
cells demonstrated the resistance to the cyto-
toxic action of the thiazoles in dose up to 
50 μM, whereas doxorubicin showed signifi-
cant cytotoxicity with the IC50 = ~20 μM.
Discussion 
The tumor targeting technologies are focused 
on creating novel agents that effectively in-
hibit, reverse or delay carcinogenesis [27] 
through selective affecting tumor cells mostly 
by impairing their antioxidant potential [28] 
or inducing apoptosis [29, 30]. Additionally, 
the potential drugs should combat tumor cells 
of the advanced stages of malignancy (metas-
tasis) that is a major cause of patients’ morta-
lity [1]. 
We have screened the anti-proliferative ac-
tivity of the novel synthesized thiazoles 5a–d 
towards human tumor cells of various tissue 
origin. The MTT assay-based evaluation of the 
survival of treated human breast adenocarci-
noma cells of MCF-7 line and human lung 
adenocarcinoma cells of A549 line showed that 
these cells were sensitive to the cytotoxic ac-
tion of the thiazoles used only in high doses 
(up to 50 μM). At the same time, these com-
pounds possessed a distinct antineoplastic ac-
tivity towards the human glioblastoma cells of 
U251 line and human melanoma cells of 
WM793 line, whereas the human myeloid 
leukemia cells of K562 line and human acute 
T-cell leukemia cells of Jurkat line were less 
sensitive to the cytotoxic action of the experi-
mental anticancer agents. The ranking of the 
toxic action of thiazoles and doxorubicin to-
wards the glioblastoma U251 cells was as 
following: 5a > doxorubicin > 5d > 5c ≈ 5b. 
IC50 of 5a for the glioblastoma cells equaled 
9.8±0.82 μM, whereas doxorubicin was less 
toxic for these cells (IC50 = 21.0±1.64 μМ). 
Obviously, the amides endowed with the ben-
zofuran moiety (5a) possess a higher antican-
cer activity [31, 32]. Glass et al. (2000) showed 
an inhibition of growth in human glioblastoma 
cell lines by the farnesyltransferase inhibitor 
SCH66336. However, the concentration of that 
inhibitor, which is required to achieve 50 % 
inhibition (IC50) ranged from 30 µM (single 
24 h treatment) to 10 µM (5 day treatment). 
This is a higher dose compared to the dose 
required for distinct effect of 5a used in our 
study. 
Malignant melanoma is a disease with a 
high mortality rate caused by rapid metastasis. 
Ciołczyk-Wierzbicka et al. [35] showed the 
inhibition of proliferation of human melanoma 
cells by using specific siRNA for silencing the 
N-cadherin gene. Its silencing arrests the cell 
growth at the G1-phase of cell cycle and in-
hibits the cell entry into the S-phase. Note wor-
thy, there are no effective chemotherapies for 
the melanoma treatment [33]. The immuno-
modulating approaches used in clinics are still 
very costly and possess high general toxi-
city [34].
During studying the anti-proliferative activ-
ity of the synthesized thiazoles towards the 
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human melanoma WM793 cells, we have 
found that 5a was also the most cytotoxic agent 
(IC50 = 7.2±0.48 μM) the action of which was 
comparable with the action of doxorubicin 
(IC50 = 6.1±0.38 μM). The toxicity rank of 
thiazoles and doxorubicin for the melanoma 
WM793 cells was: doxorubicin ≈ 5a > 5b > 
5c > 5d.
The synthesized thiazoles were also found 
to be toxic for leukemia cells ‒ the human 
myeloid leukemia cells of K562 line and the 
human acute T-cell leukemia cells of Jurkat 
line, however, demonstrated their cytotoxicity 
only at high doses. The ranking of the toxic 
action of thiazoles and doxorubicin on the 
leukemia K562 cells was the following: doxo-
rubicin (15.2±1.14 μM) > 5c (40.0±2.65 μM) 
> 5b > 5d > 5a. Thus, the rank of toxicity of 
the 5a for these leukemia cells growing only 
in suspension is opposite to the rank found for 
the glioblastoma and melanoma cells growing 
in the monolayer culture. Thus, the role of 
silencing N-cadherin (participates in cell at-
tachment) for the inhibition of melanoma cells 
should be reminded here [35]. Doxorubicin 
was the most effective inhibitor of growth of 
the human acute T-cell leukemia cells of Jurkat 
line, and the rank of inhibitory effects dropped 
in the following manner: doxorubicin (IC50 = 
0.7±0.05 μM) > 5a (IC50 = 27.0±2.13 μM) > 
5c > 5b >5d. Obviously, amides 5 endowed 
with benzofuran moiety (5a) have a higher 
anticancer activity [31, 32].
It was also shown that thiazoles were not 
toxic for human embryonic kidney HEK293 
cells, while doxorubicin had high cytotoxity 
towards these cells (IC50 was 5.7±0.42 μM).
The tested thiazole derivatives showed a 
broad spectrum of the anti-proliferative acti-
vi ty against human tumor cells of different 
tissue origin and the melanoma and glioma 
cells appeared to be more sensitive to the ac-
tion of these derivatives comparing to human 
leukemia cells.
Conclusion
Four novel thiazole derivatives were synthe-
sized and screened for their anticancer acti-
vi ty in vitro. These derivatives selectively 
inhibited the growth of human tumor cells, 
and 5a was the most potent agent demonstrat-
ing a selective action towards the glioma and 
melanoma cells, comparing to the leukemia 
cells. Thus, the thiazole derivatives are a 
perspective source of the innovative antican-
cer agents.
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Антинеопластична активність нових похідних 
тіазолів
Н. С. Фінюк, В. П. Гренюх, Ю. В. Остап’юк, 
В. С. Матійчук, Д. А. Фролов, М. Д. Обушак, 
Р. С. Стойка, А. М. Бабський
Створення нових ефективних субстанцій для викорис-
тання у протипухлинній хіміотерапії є актуальним 
напрямком медичної хімії. Мета. Дослідити цитоток-
сичну дію нових похідних тіазолу щодо пухлинних 
клітин різного тканинного походження. Мето ди. Чо-
ти ри нові N-ацильованих 2-аміно-5-бензил-1,3-тіазолів 
(субстанції 5a-d) були синтезовані взаємодією 2-аміно-
5-R-бензил-1,3-тіазолів з ацилхлоридами у середовищі 
діоксану за наявності триетиламіну. Для дослідження 
протипухлинної активності похідних тіазолу викорис-
товували МТТ-тест. Результа ти. Вста новлено, що 
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деякі похідні тіазолу мають антинеопластичну актив-
ність щодо пухлинних клітин різного тканинного по-
ходження. Показано селективну антигліомну та анти-
меланомну дію досліджуваних сполук. Речовина 5а 
має найбільш виражену цитотоксичну дію щодо клітин 
лінії U251 гліобластоми людини і лінії WM793 мела-
номи людини. Синтезовані сполуки мають низьку 
токсичність щодо псевдонормальних ембріональних 
клітин нирки. Висновок. Нове похідне тіазолу (речо-
вина 5а) є перспективним цитотоксичним чинником 
для дії на клітини гліобластоми і меланоми.
К л юч ов і  с л ов а: похідні тіазолу, 2-аміно-5-бензил-
1,3-тіазоли, протипухлинна активність, лейкоз, гліо-
бластома, меланома.
Антинеопластическая активность новых 
производных тиазола
Н. C. Финюк, В. П. Гренюх, Ю. В. Остапюк, 
В. С. Матийчук, Д. А. Фролов, M. Д. Обушак, 
Р. С. Стойка, А. М. Бабский
Разработка и синтез новых производных тиазола яв-
ляются перспективным направлением медицинской 
химии и противоопухолевой терапии. Цель. Изучение 
цитотоксического действия новых производных тиа-
зола в отношении злокачественных клеток различно-
го тканевого происхождения. Методы. Четыре новых 
N-ацилированных 2-амино-5-бензил-1,3-тиазола (5a–
d) были синтезированы взаимодействием 2-ами-
но-5-R-бензил-1,3-тиазолов с ацилхлоридами в при-
сутствии триэтиламина в среде диоксана. Исследо ва-
ние противоопухолевой активности тиазолов прово-
дили с использованием МТТ-анализа. Результаты. 
Уста нов лено, что производные тиазола оказывают 
противоопухолевое действие на некоторые типы опу-
холей. Было подтверждено селективное антиглиомное 
и антимеланомное действие соединений. Соединение 
5а проявляет наиболее выраженное цитотоксическое 
действие на опухолевые клетки U251 глиобластомы 
человека и WM793 меланомы человека. Исследованные 
соединения обладают низкой токсичностью по отно-
шению к псевдо-нормальным эмбриональным клеткам 
почек. Вывод. Соединение 5а является перспектив-
ным токсическим агентом для клеток глиобластомы 
и меланомы.
К л юч е в ы е  с л ов а: производные тиазола, 2-амино-
5-бензил-1,3-тиазолы, противоопухолевая активность, 
лейкоз, глиобластома, меланома. 
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